What is the recommended dose of Ranitidine (Zantac) for children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 8, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ranitidine Dosing in Children

The recommended dose of ranitidine for children aged 1 month to 16 years is 5-10 mg/kg/day divided into 2-3 doses for GERD or peptic ulcer disease, with a maximum of 300 mg/day, according to FDA labeling and American Academy of Pediatrics guidelines. 1, 2

Standard Oral Dosing by Indication

Treatment of Duodenal and Gastric Ulcers

  • 2-4 mg/kg twice daily (maximum 300 mg/day) for active ulcer treatment 2
  • Maintenance dosing: 2-4 mg/kg once daily (maximum 150 mg/day) 2

GERD and Erosive Esophagitis

  • 5-10 mg/kg/day divided into 2 doses for GERD treatment 1, 2
  • For erosive esophagitis specifically, the higher end of this range (closer to 10 mg/kg/day) is typically needed 1

Intravenous Dosing for Critically Ill Children

For stress ulcer prophylaxis in pediatric intensive care patients, a minimum of 3 mg/kg/day IV is required, with doses titrated to maintain gastric pH ≥4. 3

  • The commonly cited 2-4 mg/kg/day range results in poor gastric pH control in 36% of critically ill children 3
  • Optimal IV dosing: 1.5 mg/kg every 6 hours (6 mg/kg/day total) achieves pH ≥4 in 80% of critically ill children 4
  • Doses below 3 mg/kg/day result in poor control in 71% of patients versus only 19% with ≥3 mg/kg/day 3

Critical Pitfall in ICU Dosing

The standard pediatric reference dosing of 2-4 mg/kg/day is inadequate for critically ill children due to altered pharmacokinetics in this population. 3 Always start with at least 3 mg/kg/day and titrate upward based on gastric pH monitoring. 3

Age-Specific Considerations

Neonates and Preterm Infants

  • **Preterm infants (<37 weeks): 0.5 mg/kg twice daily** to maintain gastric pH >4 5
  • Term neonates: 1.5 mg/kg three times daily 5
  • Preterm infants require significantly smaller doses due to prolonged drug effect and delayed time to peak pH 5
  • Insufficient data exists for neonates <1 month of age to make definitive dosing recommendations 2

Children 4-11 Years

  • A single 75 mg dose (the over-the-counter strength) effectively controls intragastric acidity for 5-6 hours in this age group 6
  • This translates to approximately 2-3 mg/kg per dose for average-weight children in this age range 6

Intramuscular Dosing for Anaphylaxis

For anaphylaxis management, ranitidine IM dose is 1 mg/kg (maximum 50 mg) as second-line therapy combined with diphenhydramine. 7, 1, 8

  • This is never administered as monotherapy—epinephrine remains first-line treatment 8
  • The combination of diphenhydramine plus ranitidine is superior to diphenhydramine alone 7, 8
  • For IV administration in anaphylaxis, dilute in 20 mL D5W and administer over 5 minutes 7, 8

Renal Impairment Adjustments

For creatinine clearance <50 mL/min, reduce dosing to 150 mg every 24 hours in adolescents, with proportional reductions for younger children. 2

  • Hemodialysis removes ranitidine; time doses to coincide with the end of dialysis sessions 2
  • Monitor closely and adjust frequency cautiously based on clinical response 2

Formulation and Administration

  • Effervescent tablets (25 mg dissolved in 5 mL water) are preferred over peppermint syrup by 71% of children aged 4-8 years 9
  • Better taste acceptance with effervescent formulation may improve compliance 9
  • Available as 15 mg/mL syrup or 25 mg effervescent tablets 1, 9

Important Limitations

  • Tachyphylaxis develops within 6 weeks of continuous use 1
  • Ranitidine is less effective than PPIs for healing erosive esophagitis 1
  • Requires 2-3 times daily dosing due to only 6-hour duration of acid suppression 1
  • Note: Ranitidine was withdrawn from the US market in 2020 due to NDMA contamination concerns, though dosing guidelines remain relevant for understanding H2-blocker pharmacology in children

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.